logo
  

UK House Price Growth Accelerates Ahead Of Covid-19 Pandemic

ukhouseprices nov30 01may20 lt

UK house prices increased at the fastest pace since 2017 before the coronavirus pandemic struck the economy, data published by the Nationwide Building Society showed Friday.

House prices increased 3.7 percent on a yearly basis in April, faster than the 3 percent rise in March. The annual growth was forecast to ease to 2.5 percent. The latest increase was the strongest since February 2017.

The mortgage lender said the impact of the pandemic was not fully captured as the house price index was designed using mortgage approval data, and there is a lag between mortgage applications being submitted and approved.

Month-on-month, house prices grew unexpectedly by 0.7 percent after climbing 0.8 percent in the previous month. Prices were forecast to fall 0.3 percent.

Robert Gardner, Nationwide's chief economist, said housing market activity is now grinding to a halt as a result of the measures implemented to control the spread of the virus, and where the government has recommended not entering into housing transactions during this period.

Lack of transactions will make gauging house price trends difficult in the months ahead, he noted.

According to Gardner, the medium-term outlook for the housing market is also highly uncertain.

Although economic activity is set to contract significantly in the near term, policies adopted to support the economy should set the stage for a rebound once the shock passes, he observed.

These same measures should also help ensure the impact on the housing market will ultimately be much less than would normally be associated with an economic shock of this magnitude, Gardner added.

For comments and feedback contact: editorial@rttnews.com

Economic News

What parts of the world are seeing the best (and worst) economic performances lately? Click here to check out our Econ Scorecard and find out! See up-to-the-moment rankings for the best and worst performers in GDP, unemployment rate, inflation and much more.

In this week's video, we highlight Roche's pioneering approach for weight loss and glucose control. Meanwhile, the EMA has taken strict action on certain preterm birth drugs and Bayer has downsized its staff. In a breakthrough for cancer treatment, the FDA has approved a groundbreaking T-cell engager therapy. Amid progress, setbacks emerge as another ALS drug study has faltered, following closely on the heels of Amylyx Pharma's recent decision to withdraw its FDA-approved ALS drug, Relyvrio.

View More Videos
Follow RTT